Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:APLSNASDAQ:LYELNYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.43-0.7%$3.28$2.71▼$4.73$655.98M1.5985,628 shs143,382 shsAPLSApellis Pharmaceuticals$18.72-0.5%$18.71$16.10▼$43.76$2.36B0.732.30 million shs327,743 shsLYELLyell Immunopharma$9.51+19.0%$8.75$7.65▼$53.90$2.81B-0.2554,038 shs145,012 shsOGNOrganon & Co.$9.62+1.9%$10.71$8.01▼$23.10$2.50B0.753.32 million shs904,985 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+2.68%0.00%-3.90%-0.29%+0.88%APLSApellis Pharmaceuticals-1.67%+11.43%-7.47%-27.62%-53.08%LYELLyell Immunopharma-2.80%-2.70%-13.38%-42.93%-84.87%OGNOrganon & Co.+2.39%+3.45%-1.72%-34.68%-55.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.0503 of 5 stars3.50.00.00.02.72.50.6APLSApellis Pharmaceuticals4.5904 of 5 stars4.32.00.04.43.12.50.6LYELLyell Immunopharma1.7039 of 5 stars2.80.00.00.01.15.00.6OGNOrganon & Co.4.9149 of 5 stars3.34.01.73.71.83.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5060.58% UpsideAPLSApellis Pharmaceuticals 2.62Moderate Buy$40.05113.98% UpsideLYELLyell Immunopharma 1.50Reduce$20.00110.30% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0087.21% UpsideCurrent Analyst Ratings BreakdownLatest ABUS, LYEL, APLS, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025APLSApellis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$26.00 ➝ $29.005/22/2025APLSApellis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $41.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/14/2025APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$30.00 ➝ $20.005/9/2025APLSApellis PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$75.00 ➝ $52.005/9/2025APLSApellis PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$41.00 ➝ $23.005/8/2025APLSApellis PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$21.00 ➝ $18.005/8/2025APLSApellis PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$28.00 ➝ $20.005/8/2025APLSApellis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$30.00 ➝ $26.005/8/2025APLSApellis PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$55.00 ➝ $47.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.40M102.45N/AN/A$0.63 per share5.44APLSApellis Pharmaceuticals$775.84M3.03N/AN/A$1.64 per share11.41LYELLyell Immunopharma$65K43,210.22N/AN/A$2.60 per share3.66OGNOrganon & Co.$6.29B0.40$3.08 per share3.12($0.27) per share-35.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$72.85M-$0.41N/AN/AN/A-1,137.65%-68.18%-51.55%7/30/2025 (Estimated)APLSApellis Pharmaceuticals-$528.63M-$1.79N/AN/AN/A-34.97%-103.11%-28.96%7/30/2025 (Estimated)LYELLyell Immunopharma-$234.63M-$1.25N/AN/AN/A-323,792.09%-34.64%-30.02%8/6/2025 (Estimated)OGNOrganon & Co.$864M$2.882.892.570.9013.49%431.62%8.03%8/5/2025 (Estimated)Latest ABUS, LYEL, APLS, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/13/2025Q1 2025LYELLyell Immunopharma-$3.80-$3.60+$0.20-$0.18N/A$0.01 million5/7/2025Q1 2025APLSApellis Pharmaceuticals-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 million3/12/2025Q4 2024LYELLyell Immunopharma-$4.00-$14.40-$10.40-$0.72N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.83%+25.99%2.78%N/ALatest ABUS, LYEL, APLS, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A7.027.02APLSApellis Pharmaceuticals1.914.363.73LYELLyell ImmunopharmaN/A13.4313.43OGNOrganon & Co.17.731.701.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%APLSApellis Pharmaceuticals96.29%LYELLyell Immunopharma66.05%OGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%APLSApellis Pharmaceuticals6.50%LYELLyell Immunopharma25.10%OGNOrganon & Co.1.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.53 million181.91 millionOptionableAPLSApellis Pharmaceuticals770125.68 million115.93 millionOptionableLYELLyell Immunopharma270295.34 million218.83 millionOptionableOGNOrganon & Co.10,000259.96 million253.93 millionNot OptionableABUS, LYEL, APLS, and OGN HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGNJune 4 at 12:15 PM | accessnewswire.comLost Money on Organon & Co. (OGN)? Join Class Action Before July 22, 2025 - Contact Levi & KorsinskyJune 4 at 11:25 AM | accessnewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OrganonJune 4 at 11:10 AM | prnewswire.comOrganon & Co. (OGN) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before July 22, 2025June 4 at 9:30 AM | accessnewswire.comOGN LAWSUIT NOTICE: Lose Money on Organon & Co.? BFA Law Alerts Investors that the Class Action Could Allow Investors to Recover Losses (NYSE:OGN)June 4 at 9:17 AM | globenewswire.comShareholders of Organon & Co. (OGN): Protect Your Rights Before July 22, 2025 - Contact Levi & KorsinskyJune 4 at 7:20 AM | accessnewswire.comOGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Investors Have Opportunity to Lead Class Action Lawsuit!June 4 at 7:00 AM | accessnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Organon & Co. (OGN) Investors of July 22, 2025 DeadlineJune 4 at 5:45 AM | accessnewswire.comDid You Lose Money on Organon & Co. (OGN)? Levi & Korsinsky Urges Investors to Act Before July 22, 2025June 3 at 11:00 PM | accessnewswire.comORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJune 3 at 10:32 PM | globenewswire.comClass Action Filed Against Organon & Co. (OGN) Over Securities Violations - Contact Levi & Korsinsky TodayJune 3 at 5:30 PM | accessnewswire.comOGN Stock Alert: Organon & Co. Shareholders with Large Losses Should Contact Robbins LLP for Information on Leading the Class Action LawsuitJune 3 at 5:11 PM | globenewswire.comLost Money on Organon & Co. (OGN)? Urged to Join Class Action Before July 22, 2025 - Contact Levi & KorsinskyJune 3 at 4:00 PM | accessnewswire.comOGN STOCK NOTICE: Organon & Co. has been Sued for Fraud; Investors are Notified to Contact BFA Law before July 22 Legal DeadlineJune 3 at 3:33 PM | accessnewswire.comSecurities Fraud Class Action Filed Against Organon & Co. (OGN) - Levi & Korsinsky Reminds Investors of July 22, 2025June 3 at 12:15 PM | accessnewswire.comNYSE: OGN INVESTOR ALERT: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors of July 22, 2025 DeadlineJune 3 at 12:02 PM | globenewswire.comSecurities Class Action Lawsuit Filed Against Organon & Co. (OGN) - Levi & Korsinsky Represents ShareholdersJune 3 at 10:55 AM | accessnewswire.comContact Levi & Korsinsky by July 22, 2025 to Join Class Action Against Organon & Co. (OGN)June 3 at 9:40 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Organon & Co. of Class Action Lawsuit And Upcoming Deadlines - OGNJune 3 at 9:00 AM | accessnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Organon & Co. (OGN) Investors of July 22, 2025 DeadlineJune 3 at 8:00 AM | accessnewswire.comOrganon & Co. (NYSE:OGN) Short Interest UpdateJune 3 at 1:34 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABUS, LYEL, APLS, and OGN Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.42 -0.03 (-0.72%) As of 12:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Apellis Pharmaceuticals NASDAQ:APLS$18.72 -0.10 (-0.54%) As of 12:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Lyell Immunopharma NASDAQ:LYEL$9.51 +1.52 (+19.02%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Organon & Co. NYSE:OGN$9.62 +0.18 (+1.85%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
